Holen Sie sich die Stockscreener-App
36.75
5.45%
-2.12
Handel nachbörslich:
36.79
0.04
+0.11%
Schlusskurs vom Vortag:
$38.87
Offen:
$38.61
24-Stunden-Volumen:
1.57M
Relative Volume:
2.75
Marktkapitalisierung:
$1.18B
Einnahmen:
$4.85M
Nettoeinkommen (Verlust:
$-114.75M
KGV:
-11.31
EPS:
-3.25
Netto-Cashflow:
$-100.36M
1W Leistung:
-1.10%
1M Leistung:
+61.89%
6M Leistung:
+78.48%
1J Leistung:
+30.78%
1-Tages-Spanne:
$36.52
$38.68
1-Wochen-Bereich:
$36.21
$39.87
52-Wochen-Spanne:
$13.37
$39.87
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
36.75 | 1.55B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Can machine learning forecast Dianthus Therapeutics Inc. recovery2025 Price Targets & Free Real-Time Volume Trigger Notifications - newser.com
VIX Spike: What are Dianthus Therapeutics Inc.’s growth leversJuly 2025 Macro Moves & Weekly Setup with ROI Potential - khodrobank.com
Will a bounce in Dianthus Therapeutics Inc. offer an exitSell Signal & Free Safe Entry Trade Signal Reports - newser.com
What machine learning models say about Dianthus Therapeutics Inc.Trade Performance Summary & Long-Term Capital Growth Strategies - newser.com
Ranking Dianthus Therapeutics Inc. among high performing stocks via toolsGap Down & Free AI Powered Buy and Sell Recommendations - newser.com
What MACD signals say about Dianthus Therapeutics Inc.Dividend Hike & Real-Time Stock Movement Alerts - newser.com
Why Dianthus Therapeutics Inc. is moving todayPortfolio Return Report & Smart Allocation Stock Tips - newser.com
Sentiment analysis tools applied to Dianthus Therapeutics Inc.July 2025 Technicals & Verified Momentum Stock Watchlist - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighWhat's Next? - MarketBeat
Sentiment Watch: Is Dianthus Therapeutics Inc. stock showing strong momentum2025 Historical Comparison & Expert Curated Trade Setups - khodrobank.com
What indicators show strength in Dianthus Therapeutics Inc.Dollar Strength & Fast Gain Stock Trading Tips - newser.com
Fairmount Funds Management LLC Increases Stake in Dianthus Thera - GuruFocus
Clear Street Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy Recommendation - Nasdaq
Dianthus Therapeutics stock hits 52-week high at 38.65 USD - Investing.com India
What is Dianthus Therapeutics Inc.’s book value per shareJuly 2025 Institutional & Entry Point Confirmation Signals - خودرو بانک
Dianthus Therapeutics stock hits 52-week high at 38.65 USD By Investing.com - Investing.com UK
Dianthus Therapeutics (NASDAQ:DNTH) Given New $44.00 Price Target at Wedbush - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $65.00 at Stifel Nicolaus - MarketBeat
Alliancebernstein L.P. Lowers Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Cubist Systematic Strategies LLC Sells 32,948 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Clear Street initiates coverage on Dianthus Therapeutics stock with Buy rating - Investing.com Canada
Aug Macro: Can AZUL deliver alphaJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - خودرو بانک
Dianthus Therapeutics Closes $288 Million Public Offering of Common Stock and Pre-Funded Warrants - Global Legal Chronicle
Dianthus Therapeutics Reports Positive Phase 2 Trial Results - MSN
Ryan Savitz Sells 20,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Aug Update: What analysts say about Dianthus Therapeutics Inc. stockPortfolio Gains Summary & Risk Controlled Swing Alerts - khodrobank.com
Gap Down: Will NewHold Investment Corp III Debt Equity Composite Units benefit from green energy policiesJuly 2025 Institutional & Weekly Return Optimization Plans - خودرو بانک
Elliott Wave Theory Predicts Pullback in Dianthus Therapeutics Inc.2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
Dianthus Therapeutics Inc. recovery potential after sell offWeekly Stock Report & Short-Term High Return Ideas - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Market Leaders: What’s the fair value of GENVR stockTrade Signal Summary & Expert Verified Movement Alerts - خودرو بانک
Using data models to predict Dianthus Therapeutics Inc. stock movement2025 Market WrapUp & Weekly High Return Stock Forecasts - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Wedbush Analyst Says - Defense World
Stifel Nicolaus Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $65.00 - Defense World
Detecting support and resistance levels for Dianthus Therapeutics Inc.Weekly Trend Report & AI Enhanced Trading Alerts - newser.com
Why Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Myasthenia Gravis Data and $250M Raise - Sahm
Is Dianthus Therapeutics Inc. stock bottoming out2025 Price Action Summary & Reliable Entry Point Trade Alerts - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Earns Outperform Rating from Raymond James Financial - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Holdings Boosted by Octagon Capital Advisors LP - MarketBeat
What technical models suggest about Dianthus Therapeutics Inc.’s comebackJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):